Niceritrol

An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.

Also Known As:

Niceritrol Tetrahydrochloride; Pentaerythritoltetranicotinate; Perycit; Tetrahydrochloride, Niceritrol; Tetranicotinate, Pentaerythritol; Pentaerythritol Tetranicotinate; 3-Pyridinecarboxylic acid, 2,2-bis(((3-pyridinylcarbonyl)oxy)methyl)-1,3-propanediyl ester

Networked: 29 relevant articles (7 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Nicotinic Acids: 13
      - Niceritrol: 29
- Heterocyclic Acids
  - Nicotinic Acids: 13
    - Niceritrol: 29

Experts

1.	Hamatani, Hiroko: 1 article (12/2010)
2.	Hiromura, Keiju: 1 article (12/2010)
3.	Kayakabe, Ken: 1 article (12/2010)
4.	Kobatake, Keiko: 1 article (12/2010)
5.	Kobayashi, Satsuki: 1 article (12/2010)
6.	Kuroiwa, Takashi: 1 article (12/2010)
7.	Matsumoto, Takayuki: 1 article (12/2010)
8.	Nojima, Yoshihisa: 1 article (12/2010)
9.	Ueki, Kazue: 1 article (12/2010)
10.	Yoneda, Naohiro: 1 article (12/2010)

Related Diseases

1.	Hyperlipidemias (Hyperlipidemia) 10/01/1993 - "In conclusion, this study indicates Perycit is effective for anti-hyperlipemia as well as for aiding improvement of sexual dysfunction. " 10/01/1993 - "Perycit (Pentaerythriol Tetranicotinate), a slow releasing drug, is one of the drugs used for treating hyperlipemia. " 10/01/1993 - "This study investigates the clinical effect, both objective and subjective of Perycit on anti-hyperlipemia as well as on impotence. " 01/01/1985 - "It is concluded that Perycit has antilipemic effects in patients with idiopathic hyperlipidemia, and may be helpful in reducing the atherogenic risks in these patients. " 01/01/1985 - "In patients with hyperlipidemia superimposed with DM, although the serum lipids composition was not significantly changed after Perycit, the atherogenic risks might also be reduced as demonstrated by the decrease of the TC/HDL-C ratio."
2.	Chronic Renal Insufficiency 04/01/2003 - "Thirty-three patients with chronic renal disease whose serum Lp(a) levels were > or = 15 mg/dL were randomly (but not blindly) assigned to treatment with niceritrol (n = 16) or to an untreated control group (n = 17). " 04/01/2003 - "Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial." 04/01/2003 - "We administered niceritrol, a nicotinic acid derivative, to patients with chronic renal disease and a high serum Lp(a) level, and studied its effects on lipid metabolism, proteinuria, and renal function. " 04/01/2003 - "Lipid levels improved with niceritrol treatment, whereas the excretion of urinary protein decreased, perhaps slowing the rate of loss of renal function in chronic renal disease."
3.	Atherosclerosis 04/01/1985 - "Because flushing, the most frequent side effect of niceritrol, can be easily controlled by a low dose of ASA, and because the combination of the 2 drugs has some beneficial effects on blood rheology, this combination is considered worthwhile for treatment and prevention of atherosclerosis." 11/01/1980 - "Niceritrol is thought to be effective in preventing the development and progression of atherosclerosis because it raises the level of anti-atherogenic HDL-Ch and lowers the level of atherogenic VLDL- + LDL-Ch." 02/01/1978 - "Influence of nicotinic acid, niceritrol and beta-pyridylcarbinol on experimental hyperlipidemia and atherosclerosis in mini-pigs." 01/01/1975 - "The effect of niceritrol (pentaerythritoltetranicotinate) on experimental atherosclerosis in cholesterol-fed rabbits at different levels of plasma cholesterol." 07/15/1986 - "Prophylactic treatment of the hyperlipoproteinemia with the drugs niceritrol (Perycit) and beta-pyridylcarbinol (Ronicol) significantly reduced the elevated plasma cholesterol level and reduced the degree of atherosclerosis in the abdominal aorta and the coronary arteries. "
4.	Diabetic Neuropathies (Diabetic Neuropathy) 11/01/1994 - "Our results suggest that the C64 quantitative tuning fork is a convenient and objective tool for assessing the severity of diabetic neuropathy and that niceritrol is useful for the treatment of this disease." 11/01/1994 - "Use of the C64 quantitative tuning fork and the effect of niceritrol in diabetic neuropathy." 05/01/1992 - "Effect of niceritrol on streptozocin-induced diabetic neuropathy in rats." 07/01/1995 - "These observations suggest that ischemia/hypoxia plays an important role in the development of diabetic neuropathy, and that niceritrol has a therapeutic effect on this condition by improving endoneurial ischemia/hypoxia." 07/01/1995 - "The effect of treatment with niceritrol, a nicotinic acid derivative that acts as a vasodilator and reduces serum lipid concentrations, on 2,3-diphosphoglycerate concentration and diabetic neuropathy was also examined. "
5.	Proteinuria 12/01/2010 - "She was also treated with niceritrol, resulting in an improvement in her proteinuria and renal function. " 12/01/2010 - "After switching from pravastatin to niceritrol, a marked reduction in the proteinuria and an improvement in renal function were observed. " 04/01/2003 - "We administered niceritrol, a nicotinic acid derivative, to patients with chronic renal disease and a high serum Lp(a) level, and studied its effects on lipid metabolism, proteinuria, and renal function. "

Related Drugs and Biologics

1.	Pravastatin (Pravachol)
2.	Lipids
3.	oxidized low density lipoprotein
4.	Thyrotropin (Thyroid-Stimulating Hormone)
5.	Proteins (Proteins, Gene)
6.	Hypolipidemic Agents (Antihyperlipidemics)
7.	Atorvastatin (Lipitor)
8.	Niacin (Nicotinic Acid)
9.	Antigens
10.	Niceritrol

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Fat-Restricted Diet (Diet, Fat Restricted)
4.	Blood Component Removal (Apheresis)